ClearPoint Neuro Reports Earnings, Falls Short of Expectations

ClearPoint Neuro (NASDAQ:CLPT) announced its quarterly earnings results on Wednesday. For the quarter, the company reported an earnings per share (EPS) of ($0.20), which was below the analysts' consensus estimate of ($0.15) by $0.05, as reported by Zacks. Additionally, ClearPoint Neuro demonstrated a negative return on equity of 62.10% and a negative net margin of 59.64%. Furthermore, the company provided an update on its fiscal year 2025 guidance for EPS.

ClearPoint Neuro Stock Performance

Following the earnings report, shares of ClearPoint Neuro saw an increase of 3.0%, rising by $0.50 to reach a price of $17.22. On the trading day, the stock had a volume of 239,041 shares, compared to its average trading volume of 204,522 shares. Over the past twelve months, ClearPoint Neuro has experienced a low of $5.11 and a high of $19.22. The company's market capitalization is approximately $475.01 million, accompanied by a price-to-earnings (PE) ratio of -24.96 and a beta of 1.03. Currently, the stock has a 50-day moving average of $16.62 and a 200-day moving average of $13.78.

Analyst Insights on ClearPoint Neuro

Recently, various analysts shared their perspectives on ClearPoint Neuro's stock. Lake Street Capital raised their target price for shares from $17.00 to $30.00, assigning the company a "buy" rating in their report released on January 21st. Similarly, B. Riley increased their price target from $15.00 to $20.00, also giving ClearPoint Neuro a "buy" rating in a research report dated January 28th.

About ClearPoint Neuro

ClearPoint Neuro, Inc. is a medical device company focused mainly in the United States. The company develops and markets platforms designed for performing minimally invasive surgical procedures in the brain, utilizing magnetic resonance imaging guidance. Among its offerings is the ClearPoint system, an integrated tool used for the insertion of deep brain stimulation electrodes, biopsy needles, laser catheters, and the infusion of pharmaceuticals into the brain.

Further Information

• Five stocks we prefer over ClearPoint Neuro
• Guide to calculating Earnings Per Share (EPS)
• Market analysts weigh on investments during uncertain times
• Opportunities in high PE growth stocks
• AST SpaceMobile’s stock jumps after analyst upgrade
• Understanding Golden Cross in stock patterns
• Exploring stocks with high PEs worth analyzing

Earnings, Stocks, Performance